SARS-CoV-2 causes severe acute respiratory syndrome, which has led to significant
morbidity and mortality around the world. Since its emergence, extensive prophylactic and …

Antibody responses develop following SARS-CoV-2 infection, but little is known about their
epitope specificities, clonality, binding affinities, epitopes, and neutralizing activity. We …

The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
the cause of the coronavirus disease (COVID-19) pandemic. As of August 2021, more than …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is genetically variable,
allowing it to adapt to various hosts including humans. Indeed, SARS-CoV-2 has …

An ongoing pandemic of newly emerged SARS-CoV-2 has puzzled many scientists and
health care policymakers around the globe. The appearance of the virus was accompanied …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
with mutations in key antibody epitopes has raised concerns that antigenic evolution could …

The global spread of SARS-CoV-2/COVID-19 is devastating health systems and economies
worldwide. Recombinant or vaccine-induced neutralizing antibodies are used to combat the …

The novel coronavirus disease (COVID-19) pandemic remains a global public health crisis,
presenting a broad range of challenges. To help address some of the main problems, the …

Introduction As the global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
pandemic continues to spread, several variants have emerged. Variants B. 1.1. 7 and B …

Administration of convalescent plasma or neutralizing monoclonal antibodies (mAbs) is a
potent therapeutic option for coronavirus disease 2019 (COVID-19) caused by severe acute …